Mullooly JP, Bennett MD, Hornbrook MC, et al. 1994. Inﬂuenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization. Ann Intern Med, 121:947–52. [NCHS] National Center for Health Statistics. 1998. Health, United States. Hyattsville, MD: US Department of Health and Human Services. [NHLBI] National Heart, Lung and Blood Institute. 2003. Chronic obstruc- tive pulmonary disease. Bethesda: NHLBI, US Department of Health and Human Services. Publication No. 03–5229. Nichol KL, Lind A, Margolis KL, et al. 1995. The effectiveness of vac- cination against inﬂuenza in healthy, working adults. N Engl J Med, 333:889–93. Nichol KL, Wuorenma J, von Sternberg T. 1998. Beneﬁts of inﬂuenza vaccination for low-, intermediate, and high-risk senior citizens. Arch Intern Med, 158:1769–76. Nichol KL, Baken L, Nelson A. 1999. Relation between inﬂuenza vac- cination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease. Ann Intern Med, 130:397–403. Nichol KL. 2001. Cost-beneﬁt analysis of a strategy to vaccinate healthy working adults against inﬂuenza. Arch Intern Med, 161:749–59. Nichol KL, Mallon KP, Mendelman PM. 2003. Cost beneﬁt of inﬂuenza vaccination in healthy, working adults: an economic analysis based on the results of a clinical trial of trivalent live attenuated inﬂuenza virus vaccine. Vaccine, 21:2207–17. Neuzil KM, Wright PF, Mitchel EF, et al. 2000a. The burden of inﬂuenza illness in children with asthma and other chronic medical conditions. J Pediatr, 137:856–64. Neuzil KM, Mellen BG, Wright PF, et al. 2000b. The effect of inﬂuenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med, 342:225–31. Nordin J, Mullooly J, Poblete S, et al. 2001. Inﬂuenza vaccine effective- ness in preventing hospitalizations and deaths in persons 65 years or older in Minnesota, New York, and Oregon: data from 3 health plans. J Infect Dis, 184:665–70. Ohmitt SE, Monto AS. 1995. Inﬂuenza vaccine effectiveness in preventing hospitalization among elderly during inﬂuenza A and type B seasons. Int J Epidemiol, 24:1240–8. [OTA] Ofﬁce of Technology Assessment. 1981. Cost effectiveness of in- ﬂuenza vaccination. Annual report to US Congress. Washington, DC: Ofﬁce of Technology Assessment. Palese P, Young JF. 1982. Variation of inﬂuenza A, B and C viruses. Sci- ence, 92:1468–74. Park CL, Frank AL, Sullivan M, et al. 1996. Inﬂuenza vaccination of children during acute asthma exacerbation and concurrent prednisone therapy. Pediatrics, 98:196–200. Parker R, Loewen N, Skowronski D. 2001. Experience with oseltamivir in the control of a nursing home inﬂuenza B outbreak. Can Commun Dis Rep, 27:37–40. Patriarca PA, Arden NH, Koplan JP, et al. 1987. Prevention and control of type A inﬂuenza infections in nursing homes. Beneﬁts and costs of four approaches using vaccination and amantadine. Ann Intern Med, 107:732–40. Patriarca PA, Weber JA, Parker RA, et al. 1986. Risk factors for outbreaks of inﬂuenza in nursing homes. A case-control study. Am J Epidemiol, 124:114–19. Pauwels RA, Buist AS, Calverley PM, et al; COLD Scientiﬁc Committee. 2001. Global strategy for the diagnosis, management and prevention of COPD. NHLBI/WHO Global initiative for chronic obstructive lung disease (GOLD). Am J Respir Crit Care Med, 163:1256–76. Piedra PA, Glezen WP, Mbawuike I, et al. 1993. Studies on reactogenic- ity and immunogenicity of attenuated bivalent recombinant inﬂuenza type A (CRA) and inactivated trivalent inﬂuenza virus (TI) vaccines in infants and young children. Vaccine, 11:718–24. Preventing inﬂuenza in COPD Postma MJ, Bos JM, van Gennep M, et al. 1999. Economic evaluation of inﬂuenza vaccination. Assessment for The Netherlands. Pharmacoeco- nomics, 16(suppl 1):33–40. Pyhala R, Haanpaa M, Kleemola M, et al. 2001. Acceptable protective efﬁcacy of inﬂuenza vaccination in young military conscripts under circumstances of incomplete antigenic and genetic match. Vaccine, 19:3253–60. Rothberg MB. 2005. Cost-effective approaches to inﬂuenza prevention and treatment. Expert Rev Pharmacoeconomics Outcomes Res, 5:141–52. Saito R, Oshitani H, Masuda H, et al. 2002. Detection of amantadine- resistant inﬂuenza A virus strains in nursing homes by PCR-restriction fragment length polymorphism analysis with nasopharyngeal swabs. J Clin Microbiol, 40:84–8. Schilling M, Povinelli L, Krause P, et al. 1998. Efﬁcacy of zanamivir for chemoprophylaxis of nursing home inﬂuenza outbreaks. Vaccine, 16:1771–4. Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. 1979. Guillain-Barre syndrome following vaccination in the National Inﬂuenza Immunization Program, United States, 1976–1977. Am J Epidemiol, 110:105–23. Simonsen L, Clarke MJ, Williamson GD, et al. 1997. The impact of inﬂu- enza epidemics on mortality: introducing a severity index. Am J Public Health, 87:1944–50. Simonsen L, Fukuda K, Schonberger LB, et al. 2000. The impact of inﬂuenza epidemics on hospitalizations. J Infect Dis, 181:831–7. Sugaya N, Nerome K, Ishida M, et al. 1994. Efﬁcacy of inactivated vaccine in preventing antigenically drifted inﬂuenza type A and well-matched type B. JAMA 272:1122–6. Thompson WW, Shay DK, Weintraub E, et al. 2003. Mortality associated with inﬂuenza and respiratory syncytial virus in the United States. JAMA, 289:179–86. Thompson WW, Shay DK, Weintraub E, et al. 2004. Inﬂuenza-associated hospitalizations in the United States. JAMA, 292:1333–40. [USPSTF] US Preventive Services Task Force. 1996. Guide to clinical preventive services. Washington, DC: US Department of Health and Human Services. Vu T, Farish S, Jenkins M, et al. 2002. A meta-analysis of effectiveness of inﬂuenza vaccine in persons aged 65 years and over living in the community. Vaccine, 20:1831–6. Webster RG, Bean WJ, Gorman OT, et al. 1992. Evolution and ecology of inﬂuenza viruses. Microbiol Rev, 56:152–79. White JM, Wilson IA. 1987. Anti-peptide antibodies detect steps in protein conformational change: low-pH activation of the inﬂuenza virus hemag- glutinin. J Cell Biol, 105:2887–96. Wintermeyer SM, Nahata MC. 1995. Rimantadine: a clinical perspective. Ann Pharmacother, 29:299–310. Wright PF, Thompson J, Vaughn WK, et al. 1977. Trials of inﬂuenza A/New Jersey/76 virus vaccine in normal children: an overview of age-related antigenicity and reactogenicity. J Infect Dis, 136(Suppl):S731–41. [WHO] World Health Organization. 2002. Inﬂuenza vaccines. Wkly Epi- demiol Res, 77:229–40. [WHO] World Health Organization. Recommended composition of inﬂuenza virus vaccines for use in the 2006–2007 inﬂuenza season [online]. Accessed on 10/7/06 URL: http://www.who.int/csr/disease/ inﬂuenza/2007northreport.pdf. Ziegler T, Hemphill ML, Ziegler ML, et al. 1999. Low incidence of riman- tadine resistance in ﬁeld isolates of inﬂuenza A viruses. J Infect Dis, 180:935–9. International Journal of COPD 2007:2(1) 53